#AI News: TransPerfect Life Sciences to Present on Use of Artificial Intelligence in Clinical Trials at DIA 2017
NEW YORK - June 19, 2017 (Investorideas.com Newswire) TransPerfect Life Sciences, a specialized division of TransPerfect, the world's largest privately held provider of language and technology solutions for global business, today announced that it is presenting a session at the 2017 Drug Information Association (DIA) Annual Meeting, held June 19-21 in Chicago.
Entitled "Impact of Artificial Intelligence on E-Clinical Technology," the presentation, which kicks off a larger panel discussion, will be given by Vladimir Pyagay, TransPerfect's Product Manager for the Trial Interactive e-clinical solution.
"Recent years have witnessed the increase in usage of AI across many industries," said TransPerfect Co-CEO Phil Shawe. "The ability to apply this technology to clinical trials and healthcare has opened new possibilities for improving workflows and delivering life-changing and life-saving treatments to market more quickly."
Co-CEO Liz Elting stated, "The trend toward automation in clinical trials makes AI a very intriguing tool to consider. It has tremendous potential to disrupt the e-clinical space and the life sciences industry at large by increasing the degree to which trial stakeholders can simplify key tasks involved in bringing new therapies to patients and customers."
DIA Session #108: Artificial Intelligence/Machine Learning is being moderated and chaired by Badri Rengarajan, Medical Affairs Lead for Actelion Pharmaceuticals, and will be held on Monday, June 19 at 11:00 AM CT.
In addition to presenting this session, TransPerfect will also be exhibiting at DIA, showcasing both its services (Booth #808) and e-clinical technologies (Booth #911). Visit these adjacent booths to discuss the latest trends in e-clinical solutions and how they integrate with TransPerfect's award-winning trial support services.
Demos for Trial Interactive 9.0 and 9.1 can be scheduled by emailing firstname.lastname@example.org or at http://lifesciences.transperfect.com/dia-demo.
About TransPerfect Trial Interactive
TransPerfect's Trial Interactive solution provides a collaborative web-based platform for study start-up and eTMF that enables sponsors, CROs, IRBs, central laboratories, and other vendors to maintain and update clinical trial documentation in a secure online environment. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of TransPerfect's Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, eTMF review/reconciliation, pharmacovigilance and safety management, endpoint adjudication, and product licensing and alliance management. For more information on Trial Interactive, please contact email@example.com or +1 212.400.8848, or visit www.trialinteractive.com.
With revenues of over $560 million in the last year, TransPerfect is the world's largest privately held provider of language services and technology solutions. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ TransPerfect's GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.
TransPerfect Life Sciences
Ryan Simper +1 212.689.5555
TechSectorStocks.com - investing ideas in tech stocks- mobile payments, social media, AI and Robotics, Drone Stocks, GPS and more
Like Tech Stocks? View our Tech Stocks Directory
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.